1. U.S. Food and Drug Administration. Code of Federal Regulations Part 1271, Title 31. Human cells, tissues, and cellular and tissue based products. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=1271. Last accessed 12 Nov 2020.
2. U.S. Food and Drug Administration. Code of Federal Regulations Title 21. Parts 1–1499. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm. Last accessed 12 Nov 2020.
3. U.S. Food and Drug Administration. (2017). Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue Based Products: Minimal Manipulation and Homologous Use. Guidance for Industry and Food and Drug Administration Staff. November 2017. https://www.fda.gov/media/109176/download. Last accessed 12 Nov 2020.
4. U.S. Food and Drug Administration Investigational New Drug (IND) Application. FDA Website. https://www.fda.gov/drugs/types-applications/investigational-new-drug-ind-application. Last accessed 12 Nov 2020.
5. U.S. Food and Drug Administration. (2008). Content and review of chemistry, Manufacturing, and Control (CMC) Information for Human Somatic Cell Therapy Investigational New Drug Applications (INDs). Guidance for FDA Reviewers and Sponsors. April 2008. https://www.fda.gov/media/73624/download. Last accessed 12 Nov 2020.